http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 22 Sep 2026 07:01:24 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Edgewise+shares+preclinical+data+on+EDG-7500+for+heart+condition/27087411.html <p>Edgewise Therapeutics (Nasdaq: EWTX) released preclinical pharmacologic data on EDG-7500, an investigational oral cardiac sarcomere modulator targeting the Regulatory Light Chain (RLC), according to a company statement dated Sept. 22, 2026.</p><p>The company said preclinical models showed EDG-7500 improved cardiac relaxation while preserving systolic function and cardiac reserve. Early clinical observations in patients with symptomatic hypertrophic cardiomyopathy (HCM) were described as consistent with the preclinical findings. A peer-reviewed publication on EDG-7500's mechanism of action was also released the same day.</p><p>Edgewise said it screened more than 7,000 RLC candidates before selecting EDG-7500. "We screened more than 7,000 pharmacologically diverse RLC candidates and http://www.streetinsider.com/Corporate+News/Edgewise+shares+preclinical+data+on+EDG-7500+for+heart+condition/27087411.html Tue, 22 Sep 2026 07:01:24 -0400 EWTX http://www.streetinsider.com/FDA/Edgewise+shares+preclinical+data+on+EDG-7500+for+heart+condition/27087411.html <p>Edgewise Therapeutics (Nasdaq: EWTX) released preclinical pharmacologic data on EDG-7500, an investigational oral cardiac sarcomere modulator targeting the Regulatory Light Chain (RLC), according to a company statement dated Sept. 22, 2026.</p><p>The company said preclinical models showed EDG-7500 improved cardiac relaxation while preserving systolic function and cardiac reserve. Early clinical observations in patients with symptomatic hypertrophic cardiomyopathy (HCM) were described as consistent with the preclinical findings. A peer-reviewed publication on EDG-7500's mechanism of action was also released the same day.</p><p>Edgewise said it screened more than 7,000 RLC candidates before selecting EDG-7500. "We screened more than 7,000 pharmacologically diverse RLC candidates and http://www.streetinsider.com/FDA/Edgewise+shares+preclinical+data+on+EDG-7500+for+heart+condition/27087411.html Tue, 22 Sep 2026 07:01:24 -0400 EWTX http://www.streetinsider.com/Press+Releases/Edgewise+Therapeutics+Unveils+the+Differentiated+Mechanism+of+Action+%28MoA%29+of+its+Cardiac+Sarcomere+Modulator+EDG-7500/27087353.html <div class="xn-content"> <p class="prntac"><i>- The MoA that targets the Regulatory <person>Light Chain</person> (RLC) has shown in preclinical models to improve cardiac relaxation while preserving systolic function and cardiac reserve -</i></p> <p class="prntac"><i>-</i> <i>Company to host webcast to discuss these findings today at <chron>8:30 a.m. Eastern Time</chron></i> <i>-</i></p> <p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/us.co.bouldr" idsrc="xmltag.org" >BOULDER, Colo.</location></span>, <span class="legendSpanClass"><chron>Sept. 22, 2026</chron></span> http://www.streetinsider.com/Press+Releases/Edgewise+Therapeutics+Unveils+the+Differentiated+Mechanism+of+Action+%28MoA%29+of+its+Cardiac+Sarcomere+Modulator+EDG-7500/27087353.html Tue, 22 Sep 2026 07:00:00 -0400 EWTX http://www.streetinsider.com/PRNewswire/Edgewise+Therapeutics+Unveils+the+Differentiated+Mechanism+of+Action+%28MoA%29+of+its+Cardiac+Sarcomere+Modulator+EDG-7500/27087353.html <div class="xn-content"> <p class="prntac"><i>- The MoA that targets the Regulatory <person>Light Chain</person> (RLC) has shown in preclinical models to improve cardiac relaxation while preserving systolic function and cardiac reserve -</i></p> <p class="prntac"><i>-</i> <i>Company to host webcast to discuss these findings today at <chron>8:30 a.m. Eastern Time</chron></i> <i>-</i></p> <p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/us.co.bouldr" idsrc="xmltag.org" >BOULDER, Colo.</location></span>, <span class="legendSpanClass"><chron>Sept. 22, 2026</chron></span> http://www.streetinsider.com/PRNewswire/Edgewise+Therapeutics+Unveils+the+Differentiated+Mechanism+of+Action+%28MoA%29+of+its+Cardiac+Sarcomere+Modulator+EDG-7500/27087353.html Tue, 22 Sep 2026 07:00:00 -0400 EWTX http://www.streetinsider.com/Analyst+PT+Change/Edgewise+Therapeutics+%28EWTX%29+PT+Raised+to+%2457+at+H.C.+Wainwright/27083035.html H.C. Wainwright analyst Joseph Pantginis raised the price target on Edgewise Therapeutics (NASDAQ: EWTX) to $57.00 (from $45.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Edgewise+Therapeutics+%28EWTX%29+PT+Raised+to+%2457+at+H.C.+Wainwright/27083035.html Mon, 21 Sep 2026 07:35:57 -0400 EWTX http://www.streetinsider.com/Options/Edgewise+Therapeutics+Inc.+%28EWTX%29+2K+contracts+of+September+45+and+October+50+calls+active/27082383.html <p>Edgewise Therapeutics Inc. (NASDAQ: EWTX) 30-day option implied volatility is at 61; compared to its 52-week range of 51 to 164. Call put ratio 28 calls to 1 put with a focus on a spreader of 2K contracts of September 45 and October 50 calls.</p> http://www.streetinsider.com/Options/Edgewise+Therapeutics+Inc.+%28EWTX%29+2K+contracts+of+September+45+and+October+50+calls+active/27082383.html Mon, 21 Sep 2026 05:57:09 -0400 EWTX http://www.streetinsider.com/Press+Releases/Edgewise+Therapeutics+Announces+Upcoming+Late-Breaking+Science+Presentation+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026/26964400.html <div class="xn-content"> <p class="prntac"><i>– Presentation highlights positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) –</i></p><p><span class="legendSpanClass"><location value="LU/us.co.bouldr" idsrc="xmltag.org" >BOULDER, Colo.</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:EWTX" idsrc="xmltag.org" >Edgewise Therapeutics, Inc.</span> (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that the CIRRUS-HCM abstract was selected for a late-breaking science presentation at the <span>European Society of Cardiology (ESC) Congress</span>, taking place <chron>August 28-31</chron> in <location value="LU/de..munich" idsrc="xmltag.org" >Munich, Germany</location>. EDG-7500 is a novel, oral, selective cardiac sarcomere modulator designed to slow early contraction and improve cardiac relaxation http://www.streetinsider.com/Press+Releases/Edgewise+Therapeutics+Announces+Upcoming+Late-Breaking+Science+Presentation+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026/26964400.html Mon, 24 Aug 2026 08:00:00 -0400 A.03607790 EWTX O.20147506 O.34381710 http://www.streetinsider.com/Press+Releases/Edgewise+Therapeutics+Announces+Upcoming+Late-Breaking+Science+Presentation+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026/26964400.html <div class="xn-content"> <p class="prntac"><i>– Presentation highlights positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) –</i></p><p><span class="legendSpanClass"><location value="LU/us.co.bouldr" idsrc="xmltag.org" >BOULDER, Colo.</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:EWTX" idsrc="xmltag.org" >Edgewise Therapeutics, Inc.</span> (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that the CIRRUS-HCM abstract was selected for a late-breaking science presentation at the <span>European Society of Cardiology (ESC) Congress</span>, taking place <chron>August 28-31</chron> in <location value="LU/de..munich" idsrc="xmltag.org" >Munich, Germany</location>. EDG-7500 is a novel, oral, selective cardiac sarcomere modulator designed to slow early contraction and improve cardiac relaxation http://www.streetinsider.com/Press+Releases/Edgewise+Therapeutics+Announces+Upcoming+Late-Breaking+Science+Presentation+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026/26964400.html Mon, 24 Aug 2026 08:00:00 -0400 A.03607790 EWTX O.20147506 O.34381710 http://www.streetinsider.com/Press+Releases/Edgewise+Therapeutics+Announces+Upcoming+Late-Breaking+Science+Presentation+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026/26964400.html <div class="xn-content"> <p class="prntac"><i>– Presentation highlights positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) –</i></p><p><span class="legendSpanClass"><location value="LU/us.co.bouldr" idsrc="xmltag.org" >BOULDER, Colo.</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:EWTX" idsrc="xmltag.org" >Edgewise Therapeutics, Inc.</span> (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that the CIRRUS-HCM abstract was selected for a late-breaking science presentation at the <span>European Society of Cardiology (ESC) Congress</span>, taking place <chron>August 28-31</chron> in <location value="LU/de..munich" idsrc="xmltag.org" >Munich, Germany</location>. EDG-7500 is a novel, oral, selective cardiac sarcomere modulator designed to slow early contraction and improve cardiac relaxation http://www.streetinsider.com/Press+Releases/Edgewise+Therapeutics+Announces+Upcoming+Late-Breaking+Science+Presentation+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026/26964400.html Mon, 24 Aug 2026 08:00:00 -0400 A.03607790 EWTX O.20147506 O.34381710 http://www.streetinsider.com/Press+Releases/Edgewise+Therapeutics+Announces+Upcoming+Late-Breaking+Science+Presentation+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026/26964400.html <div class="xn-content"> <p class="prntac"><i>– Presentation highlights positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) –</i></p><p><span class="legendSpanClass"><location value="LU/us.co.bouldr" idsrc="xmltag.org" >BOULDER, Colo.</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:EWTX" idsrc="xmltag.org" >Edgewise Therapeutics, Inc.</span> (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that the CIRRUS-HCM abstract was selected for a late-breaking science presentation at the <span>European Society of Cardiology (ESC) Congress</span>, taking place <chron>August 28-31</chron> in <location value="LU/de..munich" idsrc="xmltag.org" >Munich, Germany</location>. EDG-7500 is a novel, oral, selective cardiac sarcomere modulator designed to slow early contraction and improve cardiac relaxation http://www.streetinsider.com/Press+Releases/Edgewise+Therapeutics+Announces+Upcoming+Late-Breaking+Science+Presentation+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026/26964400.html Mon, 24 Aug 2026 08:00:00 -0400 A.03607790 EWTX O.20147506 O.34381710 http://www.streetinsider.com/PRNewswire/Edgewise+Therapeutics+Announces+Upcoming+Late-Breaking+Science+Presentation+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026/26964400.html <div class="xn-content"> <p class="prntac"><i>– Presentation highlights positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) –</i></p><p><span class="legendSpanClass"><location value="LU/us.co.bouldr" idsrc="xmltag.org" >BOULDER, Colo.</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:EWTX" idsrc="xmltag.org" >Edgewise Therapeutics, Inc.</span> (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that the CIRRUS-HCM abstract was selected for a late-breaking science presentation at the <span>European Society of Cardiology (ESC) Congress</span>, taking place <chron>August 28-31</chron> in <location value="LU/de..munich" idsrc="xmltag.org" >Munich, Germany</location>. EDG-7500 is a novel, oral, selective cardiac sarcomere modulator designed to slow early contraction and improve cardiac relaxation http://www.streetinsider.com/PRNewswire/Edgewise+Therapeutics+Announces+Upcoming+Late-Breaking+Science+Presentation+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026/26964400.html Mon, 24 Aug 2026 08:00:00 -0400 A.03607790 EWTX O.20147506 O.34381710 http://www.streetinsider.com/PRNewswire/Edgewise+Therapeutics+Announces+Upcoming+Late-Breaking+Science+Presentation+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026/26964400.html <div class="xn-content"> <p class="prntac"><i>– Presentation highlights positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) –</i></p><p><span class="legendSpanClass"><location value="LU/us.co.bouldr" idsrc="xmltag.org" >BOULDER, Colo.</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:EWTX" idsrc="xmltag.org" >Edgewise Therapeutics, Inc.</span> (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that the CIRRUS-HCM abstract was selected for a late-breaking science presentation at the <span>European Society of Cardiology (ESC) Congress</span>, taking place <chron>August 28-31</chron> in <location value="LU/de..munich" idsrc="xmltag.org" >Munich, Germany</location>. EDG-7500 is a novel, oral, selective cardiac sarcomere modulator designed to slow early contraction and improve cardiac relaxation http://www.streetinsider.com/PRNewswire/Edgewise+Therapeutics+Announces+Upcoming+Late-Breaking+Science+Presentation+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026/26964400.html Mon, 24 Aug 2026 08:00:00 -0400 A.03607790 EWTX O.20147506 O.34381710 http://www.streetinsider.com/PRNewswire/Edgewise+Therapeutics+Announces+Upcoming+Late-Breaking+Science+Presentation+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026/26964400.html <div class="xn-content"> <p class="prntac"><i>– Presentation highlights positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) –</i></p><p><span class="legendSpanClass"><location value="LU/us.co.bouldr" idsrc="xmltag.org" >BOULDER, Colo.</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:EWTX" idsrc="xmltag.org" >Edgewise Therapeutics, Inc.</span> (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that the CIRRUS-HCM abstract was selected for a late-breaking science presentation at the <span>European Society of Cardiology (ESC) Congress</span>, taking place <chron>August 28-31</chron> in <location value="LU/de..munich" idsrc="xmltag.org" >Munich, Germany</location>. EDG-7500 is a novel, oral, selective cardiac sarcomere modulator designed to slow early contraction and improve cardiac relaxation http://www.streetinsider.com/PRNewswire/Edgewise+Therapeutics+Announces+Upcoming+Late-Breaking+Science+Presentation+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026/26964400.html Mon, 24 Aug 2026 08:00:00 -0400 A.03607790 EWTX O.20147506 O.34381710 http://www.streetinsider.com/PRNewswire/Edgewise+Therapeutics+Announces+Upcoming+Late-Breaking+Science+Presentation+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026/26964400.html <div class="xn-content"> <p class="prntac"><i>– Presentation highlights positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) –</i></p><p><span class="legendSpanClass"><location value="LU/us.co.bouldr" idsrc="xmltag.org" >BOULDER, Colo.</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:EWTX" idsrc="xmltag.org" >Edgewise Therapeutics, Inc.</span> (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that the CIRRUS-HCM abstract was selected for a late-breaking science presentation at the <span>European Society of Cardiology (ESC) Congress</span>, taking place <chron>August 28-31</chron> in <location value="LU/de..munich" idsrc="xmltag.org" >Munich, Germany</location>. EDG-7500 is a novel, oral, selective cardiac sarcomere modulator designed to slow early contraction and improve cardiac relaxation http://www.streetinsider.com/PRNewswire/Edgewise+Therapeutics+Announces+Upcoming+Late-Breaking+Science+Presentation+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026/26964400.html Mon, 24 Aug 2026 08:00:00 -0400 A.03607790 EWTX O.20147506 O.34381710 http://www.streetinsider.com/Analyst+PT+Change/Edgewise+Therapeutics+%28EWTX%29+PT+Raised+to+%2460+at+JPMorgan/26953952.html JPMorgan analyst Tessa Romero raised the price target on Edgewise Therapeutics (NASDAQ: EWTX) to $60.00 (from $53.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Edgewise+Therapeutics+%28EWTX%29+PT+Raised+to+%2460+at+JPMorgan/26953952.html Thu, 20 Aug 2026 09:07:48 -0400 EWTX http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Edgewise+Therapeutics%2C++++For%3A+Aug+12++Filed+by%3A+Nofi+Michael/26939216.html si-local-file:///var/storage/secattach/20260817/26939216.html http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Edgewise+Therapeutics%2C++++For%3A+Aug+12++Filed+by%3A+Nofi+Michael/26939216.html Mon, 17 Aug 2026 18:42:00 -0400 EWTX O.34381710 http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Edgewise+Therapeutics%2C++++For%3A+Aug+12++Filed+by%3A+Nofi+Michael/26939216.html si-local-file:///var/storage/secattach/20260817/26939216.html http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Edgewise+Therapeutics%2C++++For%3A+Aug+12++Filed+by%3A+Nofi+Michael/26939216.html Mon, 17 Aug 2026 18:42:00 -0400 EWTX O.34381710 http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Edgewise+Therapeutics%2C++++For%3A+Aug+12++Filed+by%3A+Russell+Alan+J/26939213.html si-local-file:///var/storage/secattach/20260817/26939213.html http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Edgewise+Therapeutics%2C++++For%3A+Aug+12++Filed+by%3A+Russell+Alan+J/26939213.html Mon, 17 Aug 2026 18:41:00 -0400 EWTX O.34381710 http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Edgewise+Therapeutics%2C++++For%3A+Aug+12++Filed+by%3A+Russell+Alan+J/26939213.html si-local-file:///var/storage/secattach/20260817/26939213.html http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Edgewise+Therapeutics%2C++++For%3A+Aug+12++Filed+by%3A+Russell+Alan+J/26939213.html Mon, 17 Aug 2026 18:41:00 -0400 EWTX O.34381710 http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Edgewise+Therapeutics%2C++++For%3A+Aug+12++Filed+by%3A+Donovan+Joanne+M./26939214.html si-local-file:///var/storage/secattach/20260817/26939214.html http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Edgewise+Therapeutics%2C++++For%3A+Aug+12++Filed+by%3A+Donovan+Joanne+M./26939214.html Mon, 17 Aug 2026 18:41:00 -0400 EWTX O.34381710 http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Edgewise+Therapeutics%2C++++For%3A+Aug+12++Filed+by%3A+Donovan+Joanne+M./26939214.html si-local-file:///var/storage/secattach/20260817/26939214.html http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Edgewise+Therapeutics%2C++++For%3A+Aug+12++Filed+by%3A+Donovan+Joanne+M./26939214.html Mon, 17 Aug 2026 18:41:00 -0400 EWTX O.34381710 http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Edgewise+Therapeutics%2C++++For%3A+Aug+12++Filed+by%3A+Derakhshan+Behrad/26939211.html si-local-file:///var/storage/secattach/20260817/26939211.html http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Edgewise+Therapeutics%2C++++For%3A+Aug+12++Filed+by%3A+Derakhshan+Behrad/26939211.html Mon, 17 Aug 2026 18:40:00 -0400 EWTX O.34381710 http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Edgewise+Therapeutics%2C++++For%3A+Aug+12++Filed+by%3A+Derakhshan+Behrad/26939211.html si-local-file:///var/storage/secattach/20260817/26939211.html http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Edgewise+Therapeutics%2C++++For%3A+Aug+12++Filed+by%3A+Derakhshan+Behrad/26939211.html Mon, 17 Aug 2026 18:40:00 -0400 EWTX O.34381710 http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Edgewise+Therapeutics%2C++++For%3A+Aug+12++Filed+by%3A+MOORE+JOHN+R/26939212.html si-local-file:///var/storage/secattach/20260817/26939212.html http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Edgewise+Therapeutics%2C++++For%3A+Aug+12++Filed+by%3A+MOORE+JOHN+R/26939212.html Mon, 17 Aug 2026 18:40:00 -0400 EWTX O.34381710 http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Edgewise+Therapeutics%2C++++For%3A+Aug+12++Filed+by%3A+MOORE+JOHN+R/26939212.html si-local-file:///var/storage/secattach/20260817/26939212.html http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Edgewise+Therapeutics%2C++++For%3A+Aug+12++Filed+by%3A+MOORE+JOHN+R/26939212.html Mon, 17 Aug 2026 18:40:00 -0400 EWTX O.34381710